Pozen News

Pozen Inc. filed Quarterly Report for the period ended 2009-09-30. Pozen Inc. is pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Oct 27, 2009 - POZEN Inc. announced today the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin and immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses of over-the-counter enteric-coated aspirin in ...

Main Category: GastroIntestinal / Gastroenterology Also Included In: Arthritis / Rheumatology Clinical Trials / Drug Trials AstraZeneca and POZEN Inc.

LONDON, Oct. 16, 2009-AstraZeneca and POZEN Inc. today announced that they have submitted a Marketing Authorisation Application in the European Union via the Decentralised Procedure for VIMOVO tablets, a product under investigation for the treatment of the signs and symptoms of osteoarthritis , rheumatoid arthritis and ankylosing spondylitis in ...

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the... CHICAGO-- --Three mutual funds rose to the highest level of a new ranking system and are being highlighted today on Zacks.com. These free "Strong Buy" picks are being made available to p... CHICAGO-- --Zacks.com releases the latest Industry ...

POZEN Inc. announced that on September 29, 2009, the United States District Court for the Middle District of North Carolina granted the Company's motion to dismiss a consolidated class action lawsuit against the Company, its chief executive officer and certain of its officers.

CHAPEL HILL, N.C. Elizabeth Cermak, a veteran executive at Johnson & Johnson, is joining pharmaceutical firm Pozen as its chief commercial officer.

Elizabeth A. Cermak has been named executive vice president, chief commercial officer of Pozen, Inc .

POZEN Inc. , announced that the U.S. Food and Drug Administration has accepted the New Drug Application for VIMOVO .

CHAPEL HILL,A N.C. The Food and Drug Administration has accepted the regulatory approval application for a drug designed to treat arthritis in patients prone to getting ulcers from their pain relievers.

Pozen is ready for a fight with Dr. Reddy's. The Chapel Hill drug maker notified investors late Wednesday that Dr.

RESEARCH TRIANGLE PARK, N.C. It's safe to say that Andrew Witty is a change agent.

John Plachetka is chairman, president and CEO of Pozen. View Larger Drugmaker Pozen on Tuesday released second-quarter earnings that topped Wall Street estimates on the bottom line but fell short on the top line.

CAMBRIDGE, Mass.-- --Outcome Sciences, Inc. , the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that Dan Levy, MS, Vice - NASHUA, N.H.-- --Colonial Electronic Manufacturers, Inc.

Pennyperformers.com "Penny Stocks that Perform" picks are: dELiA*s, Inc. , Helix Wind, Corp.

POZEN Submits New Drug Application For VIMOVO Main Category: Arthritis / Rheumatology Also Included In: Regulatory Affairs / Drug Approvals Article Date: 02 Jul 2009 POZEN Inc.

Jun 29, 2009 CytRx Corporation closed at $0.95 on a volume of 2,859,519 shares. CytRx Files Report with the FDA in Response to the Partial Clinical Hold on its Phase 2b Arimoclomol ALS Trial LOS ANGELES, Jun 30, 2009 -- CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human ...

By: Jason Napodano, CFA 0 ) Share Today Pozen announced the submission of the new drug application to the U.S. FDA, seeking marketing approval for Vimovo for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk for developing NSAID-associated ulcers.

The CEO of Pozen, which developed the migraine drug Treximet, says he remains optimistic about the drug's prospects, despite roadblocks being erected by insurers that criticize its price.